Scilex Holding Company Announces Receipt of Notice from Nasdaq

Core Viewpoint - Scilex Holding Company has received a notice from Nasdaq regarding non-compliance with listing requirements due to the late filing of its Q3 Form 10-Q for the quarter ended September 30, 2024 [1][2]. Compliance and Filing - The company has 60 calendar days from the receipt of the notice, until January 20, 2025, to submit a plan to regain compliance with Nasdaq's Listing Rule [2]. - If Nasdaq accepts the plan, the company may receive an extension of up to 180 calendar days, allowing compliance until May 19, 2025 [2]. - Scilex intends to file the Q3 Form 10-Q as soon as possible to regain compliance, and if not submitted by January 20, 2025, a plan will be submitted outlining steps to file the report [3]. Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [8]. - The company’s commercial products include ZTlido® for neuropathic pain, ELYXYB® for migraine treatment, and Gloperba® for gout flare prophylaxis [8][9]. - Scilex has three product candidates in development: SP-102 for lumbosacral radicular pain, SP-103 for acute pain, and SP-104 for fibromyalgia [9].